Results of cancer and leukemia group B protocol 8935 ☆ ☆☆ ★ ★★ ♢ ♢♢ ♦: A multiinstitutional phase II trimodality trial for stage IIIa (N2) non-small-cell lung cancer

摘要: Abstract From October 1989 to February 1992, 74 patients with mediastinoscopically staged IIIA (N2) non-small-cell lung cancer from 30 CALGB-affiliated hospitals received two cycles of preresectional cisplatin and vinblastine chemotherapy. Patients responsive or stable disease underwent standardized surgical resection radical lymphadenectomy. who sequential adjuvant therapy vinblastine, followed by thoracic irradiation (54 Gy after complete 59.4 incomplete no at 1.8 per fraction). There were radiographic responses the neoadjuvant chemotherapy, although 65 (88%) had either a response progression. During induction progressed in seven (9%). Sixty-three (86%) exploratory thoracotomy, 46 those (75%) resectable lesions. A was accomplished 23 patients, an diseased margin highest node resected. Operative mortality 3.2% (2/63). In 10 (22% having resection) pathologically downstaged. correlation between chemotherapy downstaging resection. The full protocol completed 33 (45% original cohort). Overall survival 3 years 23%. undergoing significantly improved compared not resection: 46% for (median 20.9 months), 25% 17.8 0% 8.5 months). Five deaths occurred during treatment period. total 18 (39%) are alive disease-free have died without recurrence. (J THORAC CARDIOVASC SURG 1995; 109: 473-85)